Presenting Companies


Spinal Modulation is developing its first neuromodulation product to provide an option for the millions of people living with chronic pain. Spinal Modulation was founded in 2004 by Mir Imran and Daniel Kim, M.D. In late 2005, Spinal Modulation began operations inside of InCube Labs. Through careful observation of patient needs, engagement of world renowned physicians, and recruitment of top engineering talent, Spinal Modulation is developing its first product--a novel neuromodulation device. This product is expected to address the shortcomings of current chronic pain products and help improve the lives of millions of patients living with this debilitating condition.

Blackrock is a privately held company that provides enabling tools for the neuroscience, neural engineering, and neuroprosthetics research and clinical community worldwide.  Founded in May 2008 near the Blackrock Desert in Utah, the company draws on a legacy of high tech innovation that began with Bionic Technologies, a spin-off from the University of Utah in 1997. Bionic Technologies, started by Brian Hatt and Prof. Richard A. Normann-- also the inventor of the Utah Electrode Array--was later taken over by Cyberkinetics Neurotechnologies Inc. Having taken major strides in applying the technology to the human body, the research business of CKI was then acquired by Blackrock Microsystems LLC. Blackrock caters to the immediate and future needs of the research markets. These existing markets, together with major technical breakthroughs in chronically implantable microsystems, propel us to the forefront of key clinical solutions for next-generation pharma development, healthcare, and personalized medicine.

TriGeminal Solutions, Inc. (TSI) is a healthcare-technology company that uses personalized medicine concepts to help physicians significantly improve patient outcomes and reduce costs associated with neurological diseases such as migraine. Using patented software-based techniques, TSI determines the patient-specific environmental factors that episodically increase the severity of these diseases. In the case of migraine, in a clinical trial at one of the leading headache institutes in the country, TSI successfully identified migraine triggers ― the individual-specific factors that initiate migraine attacks ― for the first time, thereby solving a difficult problem and fulfilling a long-standing need in the existing practice of medicine. In conjunction with a management system that helps patients and their physicians use the identified information, this unique capability significantly reduces the frequency, severity, and duration of headaches, and improves the quality of patients’ lives. Using this evolutionary approach, TSI’s service can help physicians achieve revolutionary results.


Click here for presenting firms from previous years.